Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility
This study has been completed.
University of Houston
First Posted: March 1, 2010
Last Update Posted: July 16, 2014
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Kevin W. Garey, University of Houston
Susceptibility testing is commonly employed in patients with bacterial infections in order to guide rational use of antibiotics; however, the use of antifungal susceptibility testing is limited due to lack of availability, costs, and delays in receiving results. The goals of antifungal susceptibility testing should mirror those of antibacterial susceptibility testing: to predict clinical response or failure. Additionally, susceptibility reports should be used as a guide for physicians when transitioning patients from parenteral to oral antifungal agents. Currently, it is unknown whether antifungal susceptibility testing impacts treatment decisions in hospitals that routinely perform Candida susceptibility testing. The purpose of this study is to evaluate the changes in antifungal treatment based on in vitro susceptibility reports and how these decisions affect mortality, recurrence of infection, and length of hospital stay in candidemia patients.
|Blood Stream Infections Candida|
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility|
Further study details as provided by Kevin W. Garey, University of Houston:
Primary Outcome Measures:
- Assess empiric choice of antifungal therapy in hospitalized patients with candidemia. [ Time Frame: Assessments made for 30-days after postivie blood culture ]
|Study Start Date:||January 2010|
|Study Completion Date:||January 2011|
|Primary Completion Date:||January 2011 (Final data collection date for primary outcome measure)|
|Hospitalized patients with candidemia|
Contacts and Locations
No Contacts or Locations Provided